门诊兔抗胸腺细胞球蛋白诱导治疗在肾移植受者中的安全性与可行性
该回顾性研究评估肾移植受者门诊外周静脉给予兔抗胸腺细胞球蛋白(rATG)诱导方案后7天内再入院趋势,共纳入1104例患者。结果显示门诊rATG相关再入院比例每年低于4%,总再入院率在2008-2014年间为9%至略高于12%,2014-2016年低于10%,共节省1124个住院日,平均每年125天。结论认为门诊rATG给药可行、安全且未增加给药后早期再入院。
要点
- 门诊外周静脉rATG诱导方案未增加给药后7天内再入院。
- 每年因门诊rATG相关再入院比例低于4%。
- 该方案共节省1124个住院日,平均每年125天。
核心结论
- 门诊给予rATG可行、安全,且未增加给药后直接时期的再入院。
研究设计与样本
- 回顾性研究,纳入2008年1月1日至2016年2月29日期间接受门诊rATG方案的肾移植受者1104例。
主要发现
- 2008-2015年肾移植数量及每年门诊rATG给药次数呈上升趋势。
- 方案实施后2008-2014年总再入院率范围为9%至略高于12%,2014-2016年保持在低于10%。
- 研究期间每年门诊rATG输注可能导致的rATG相关再入院比例低于4%。
- 共节省1124个住院日,平均每年125天。
关键数值与推荐
- rATG给药与导致再入院的不良反应的相关性采用世界卫生组织-乌普萨拉监测中心因果关系评估量表和Naranjo不良反应概率量表判定。
临床怎么用
- 肾移植受者可在门诊通过外周静脉完成rATG诱导疗程,以减少住院时间和药物支出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kidney transplant induction therapy often includes inpatient administration of rabbit antithymocyte globulin (rATG) over multiple days. To reduce hospital length of stay (LOS) and drug expenditures, the rATG induction course was completed in the outpatient setting via peripheral intravenous administration. The present study assesses early readmission trends ascribable to an outpatient rATG administration protocol to ensure initial reduction in hospital LOS is sustained early after discharge. METHODS: This was a retrospective study of kidney recipient outcomes for patients transplanted between January 1, 2008, and February 29, 2016, immediately following implementation of an outpatient rATG protocol. Readmission data within 7 days of outpatient rATG administration were collected. The relatedness of rATG administration to an adverse drug reaction resulting in readmission was determined by the World Health Organization-Uppsala Monitoring Centre Causality Assessment Scale and the Naranjo Adverse Drug Reaction Probability Scale. RESULTS: A total of 1104 patients received outpatient doses of rATG and were included. An upward trend in kidney transplant volume and outpatient rATG administrations per year was found from 2008-2015. Following protocol implementation, the percentage of overall readmissions ranged from 9% to just over 12% from 2008-2014 and remained less than 10% for 2014 through 2016. The percentage of outpatient rATG infusions that potentially led to rATG-related readmissions was less than 4% per year over the study period. A total of 1124 hospital days were saved, 125 days per year on average. CONCLUSIONS: Outpatient administration of rATG is feasible, safe, and did not increase readmissions in the period directly following administration. The findings of this analysis support our continued use of the outpatient rATG protocol at our institution.
引用
- Varga AN, Johnson D, Sawinski DL, et al. Safety and Feasibility of Outpatient Rabbit Antithymocyte Globulin Induction Therapy Administration in Kidney Transplant Recipients. Pharmacotherapy. 2018. PMID: 29665038. doi:10.1002/phar.2116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。